CytoDyn (CYDY) AGM 2024 summary
Event summary combining transcript, slides, and related documents.
AGM 2024 summary
12 Jan, 2026Opening remarks and agenda
Meeting called to order at 9:31 A.M. Pacific Time on November 22, 2024, as a virtual webcast.
Chair presided, with the Chief Legal Officer acting as Secretary and recording minutes.
Attendees included board members, executive team, transfer agent, and independent auditors.
Meeting conducted in accordance with company bylaws and Delaware law.
Notice of meeting and proxy materials were mailed to stakeholders of record as of September 30, 2024.
Board and executive committee updates
Five director nominees were presented for election to serve a one-year term until the 2025 annual meeting.
Nominating and Corporate Governance Committee recommended the slate of nominees.
Shareholder proposals
Three items were up for vote: election of directors, ratification of the independent accounting firm, and approval of executive compensation.
Board unanimously recommended approval of all proposals.
Latest events from CytoDyn
- Leronlimab demonstrates promising efficacy and safety in advanced cancer trials, with key milestones ahead.CYDY
Life Sciences Virtual Investor Forum Conference - Net loss of $42.7M, ongoing liquidity risks, and urgent need for new funding despite clinical progress.CYDY
Q4 2026 - Promising phase II data and rapid enrollment highlight strong momentum for leronlimab in oncology.CYDY
16th Annual LD Micro Invitational Conference - Leronlimab shows robust ctDNA declines and tumor control in advanced colorectal cancer.CYDY
Study update - Clinical-stage biotech registers 278M shares for resale; future hinges on leronlimab and new funding.CYDY
Registration filing - Quarterly net loss of $4.7M, major notes extended, and ongoing going concern risk persists.CYDY
Q3 2026 - Net loss of $22.6 million and legal settlement accrual raise going concern risks.CYDY
Q2 2026 - Up to 120M shares may be sold for $30M to fund oncology trials, with notable dilution risk.CYDY
Registration Filing - Biotech aims to raise $100M for oncology drug development, facing high financial and regulatory risk.CYDY
Registration Filing